Journals / Retina-Vitreus / 2000 / Cilt: 8 - Sayı: 1

Visual prognosis following intravitreal injection of tissue plasminogen activator for acute central retinal vein occlusion

Akut santral retinal ven tıkanıklığında intravitreal doku plazminojen aktivatörünün görsel prognoza etkisi

Pages
34–39
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was no statistically significant difference in visual improvement rate between ischemic and non-ischemic group after tPA injection, (p > 0.05) CONCLUSION: Intravitreal injection of tPA administered early in the course of central retinal vein occlusion may be of benefit to improve the vision without catastrophic side effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:INTRODUCTION: In this study we aimed to investigate the effect of intravitreal injection of tissue plasminogen activator (tPA) on visual prognosis of patients with acute central retinal vein occlusion (CRVO).
📊
Key Findings & Data:MATERIALS AND METHODS: A pilot study was performed in a consecutive series of 23 patients who had an early onset of CRVO (developed < 21 days with visual symptoms).
💡
Conclusion & Impact:There was no statistically significant difference in visual improvement rate between ischemic and non-ischemic group after tPA injection, (p > 0.05) CONCLUSION: Intravitreal injection of tPA administered early in the course of central retinal vein occlusion may be of benefit to improve the vision without catastrophic side effects.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Retinal ven tıkanıklığı · Doku plazminojen aktivatörü · Görme keskinliği

Abstract

INTRODUCTION: In this study we aimed to investigate the effect of intravitreal injection of tissue plasminogen activator (tPA) on visual prognosis of patients with acute central retinal vein occlusion (CRVO). MATERIALS AND METHODS: A pilot study was performed in a consecutive series of 23 patients who had an early onset of CRVO (developed < 21 days with visual symptoms). After informed consent, affected eyes of the patients received intravitreal injection of 65-100µg of tPA. We evaluated the visual results and performed statistical analysis to compare the visual outcome in ischemic and non-ischemic subgroup of patients. RESULTS: Visual acuity improved to 20/40 or better in 8 of 23 (34%) patients. Visual acuity improved or stabilized in 15 of 23 (65%) cases. None of the patients developed rhegmatogenous retinal detachment, intraocular infection or neovascular glaucoma. There was no statistically significant difference in visual improvement rate between ischemic and non-ischemic group after tPA injection, (p > 0.05) CONCLUSION: Intravitreal injection of tPA administered early in the course of central retinal vein occlusion may be of benefit to improve the vision without catastrophic side effects.

Özet

GİRİŞ: Bu çalışmada akut dönemdeki santral retinal ven tıkanıklığı (SRVT) olgularında intravitreal doku plazminojen aktivatörü (dPA) uygulamasının görsel prognoza etkisini araştırmak amaçlanmıştır. GEREÇ ve YÖNTEM: Başlangıç dönemindeki ( 0.05) SONUÇ: SRVT'nda erken dönemde uygulanan intravitreal dPA enjeksiyonu ciddi yan etkilere yol açmaksızın iyi bir görsel prognoz sağlamıştır.

🔖

Cite This Article

TUNÇ, M., LAHEY, J. M., FUNG, D., KEARNEY, J. (2000). Visual prognosis following intravitreal injection of tissue plasminogen activator for acute central retinal vein occlusion. Retina-Vitreus, Cilt: 8 - Sayı: 1, 34–39. https://ajindex.com/articles/305435

References (14)

  1. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98:271-282
  2. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central retinal vein occlusion. The central vein occlusion study group M report. Ophthalmology 1995; 102:1425-1433
  3. Central Retinal Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischémie central vein occlusion. The central vein occlusion study group N report. Ophthalmology 1995; 102: 1434-1444
  4. Öncel M, Peyman GA, Khoobehi B. Tissue plas-minogen activator in the treatment of experimental vein occlusion. Retina 1989; 9: 1-7
  5. Holmes DR, Califf RM, Topol EJ. Lessons we have learned from the GUSTO Trial. J Am Coll Cardiol 1995; 25(Suppl): 10S-17S
  6. Lambrou FH, Snyder RW, Williams GA, Lewandowski M. Treatment of experimental intravitreal fibrin with tissue plasminogen activator. Am J Ophthalmol 1987;104: 619-623
  7. Kimura AE, Reddy CV, Folk JC, et al. Removal of subretinal hemorrhage facilitated by preoperative intravitreal tissue plasminogen activator. Retina 1994; 14: 83-84
  8. Takeuchi A, Kricorian G, Hao X-Y, Kenney JW, Marmor M. The rate and source of albumin entry into saline filled experimental retinal detachments. Invest Ophthal Vis Sei 1994; 35: 3792-3798
  9. Coll GE, Sparrow JR, Marino vie A, Chang S.Effect of intravitreal tissue plaminogen activator on experimental subretinal hemorrhage. Retina 1995; 15:319-326
  10. Loren M. Thrombus age and tissue plasminogen activator mediated thrombolysis in rats. Thrombus Research 1989; 56:67-76
  11. Gaff ney PJ, Templeman AD, Curtis AD, Campbell PJ. The stability of tissue plasminogen activator (tPA). Throbm Haemostas 1983; 50:650-651
  12. Johnson MW, Olsen KR, Hernandez E, et al. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol 1990; 108: 259-263
  13. Fekrat S, Finkelstein D. Current concepts in the management of central retinal vein occlusion. Curr Opin ÜOphthalmol 1997; 8: 50-54
  14. Central Vein Occlusion Study Group. Baseline and early natural history report. Arch Ophthalmol 1993; 111:1087-1095.: 15. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Şamama MM. Prognostic factors for retinal vein occlusion. A prospective study of 175 cases. Ophthalmology 1996; 103-551-560., 16. Quinlan PM, Elman MJ, Bhatt AK, Mardesich P, Enger C. The natural cou